Psychiatry & Biobehavioral Sciences and Pediatrics
Los Angeles Biomedical Research Institute
United States of America
Dr. Grob's clinical interests include mood and anxiety disorders, as well as the self-medication hypothesis of substance abuse as it applies to substance abuse. His research has included the first FDA approved Phase 1 study of the physiological and psychological effects of MDMA (3,4-methlyenedioxymethamphetamine), a multi-national, collaborative study of the Amazonian plant hallucinogen decoction, ayahuasca, in Brazil and a pilot investigation of the safety and efficacy of psilocybin in the treatment of anxiety in adult patients with advanced-stage cancer. He is a founding member of the Heffter Research Institute, which is devoted to fostering and funding research on psychedelics.
Mood and anxiety disorders,Phase 1 study of the physiological and psychological effects of MDMA (3,4-methlyenedioxymethamphetamine)
Statement on ayahuasca. Int J Drug Policy. 2012
PTSD symptom reports of patients evaluated for the New Mexico Medical Cannabis Program. J Psychoactive Drugs. 2014
A new treatment model for social anxiety in autistic adults. Prog Neuropsychopharmacol Biol Psychiatry. 2016